Recruitment and Randomization
ovarian cancer, disease stage, Tumor, Cancer
OVARIAN CANCER, TUMOR, MAY, EPITHELIAL OVARIAN CANCER, CANCER
From May 1, 2010, to March 20, 2014, patients who were diagnosed with ovarian cancer and living in Connecticut were recruited to the WALC trial using the Rapid Case Ascertainment Shared Resource of the Yale Cancer Center, a field agent of the Connecticut Tumor Registry that identified patients with ovarian cancer from all hospitals in Connecticut. Individuals were also recruited at 2 additional study sites: Dana-Farber Cancer Institute in Boston, Massachusetts, and Geisinger Health System in Danville, Pennsylvania. Some patients living outside Connecticut learned about WALC trial through national support groups, physicians, or brochures in clinic waiting rooms and were screened via telephone. If eligible and interested, participants completed baseline questionnaires and were randomized 1:1 to a 6-month exercise intervention arm or an attention control arm.Eligibility criteria included (1) ability to speak English, (2) aged 18 to 75 years, (3) diagnosis of stage I to stage IV invasive epithelial ovarian cancer within the past 4 years, (4) completion of chemotherapy (if received) at least 1 month prior to randomization, (5) current exercise routine of less than 90 minutes per week, and (6) receipt of physician consent to start an exercise program. Randomization was block stratified by disease stage (stage I and II vs stage III and IV) and age (≥55 vs <55 years).